hema.to
The company provides end-to-end AI software solutions for clinical flow cytometry, specifically designed to automate population classification and reporting. Its platform, CellStudio, assists hematopathology laboratories by replacing manual gating with reproducible, panel-independent AI pipelines to reduce analysis time. The technology supports diagnostic workflows for conditions such as B-cell non-Hodgkin lymphoma (B-NHL) and is used by clinical researchers and medical directors.
Visit websiteMunich, Germany
Healthtech
Artificial Intelligence
Diagnostics
Biotechnology
Funding summary
- Total raised
- €7.2M
- Funding rounds
- 2
Investors in hema.to
Investors on record for hema.to. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like hema.to?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors